Resumen de Investigación

Analyzed using Evidence Intelligence™

Liraglutide improves beta-cell function in type 2 diabetes

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 12 de septiembre de 2026

Key finding

Liraglutide increased the disposition index [B total × ISI composite, by 40% (n=24, p<0.001)].

The study investigated the effects of liraglutide on beta-cell function in individuals with well-controlled type 2 diabetes, finding a significant improvement in the disposition index.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

The study investigated the effects of liraglutide on beta-cell function in individuals with well-controlled type 2 diabetes, finding a significant improvement in the disposition index.

Clinical relevance

Improving beta-cell function is crucial for managing type 2 diabetes effectively. Liraglutide's ability to enhance insulin secretion and reduce blood sugar levels could lead to better long-term outcomes for patients, potentially reducing the risk of diabetes-related complications.

Keep in mind

Sample size for some outcomes was small, limiting generalizability. Effectiveness of liraglutide compared to metformin and placebo remains unclear. No long-term follow-up data were provided.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Christian A, Preman K, Anders J, et al. The insulinotropic drug liraglutide improves beta-cell function in well-controlled type 2 diabetes. Diabetology & Metabolic Syndrome. 2019;11:42. doi:10.1186/s13098-019-0438-6

View DOI View on PubMed View on PMC

Efectos Principales

Liraglutide increased the disposition index by 40% (n=24, p<0.001).

Post-prandial insulin and glucose were reduced by metformin in combination with liraglutide.

Liraglutide may reduce post-prandial glucose without increasing insulin concentration.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Liraglutide and Disposition Index, Glucagon, Insulin clearance, and 2 more.

This study contributes evidence to

Intervention

Liraglutide

Outcome

Disposition Index

Evidence topic

Glycemic Control

Primary intervention

Liraglutide

Primary outcomes

Disposition Index
Glucagon
Insulin clearance

Evidence topics

Glycemic Control Post-Meal and OGTT Glucose GLP-1 Receptor Agonists Liraglutide

Primary intervention

Liraglutide

Primary outcomes

Disposition Index Glucagon Insulin clearance

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and Postprandial and OGTT Glucose

Evidencia relacionada

Tema de evidencia

Glycemic Control

Guardar evidencia

Tema de evidencia

Post-Meal and OGTT Glucose

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Disposition Index

Liraglutide → Disposition Index

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Glucagon

Liraglutide → Glucagon

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Insulin clearance

Liraglutide → Insulin clearance

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Post-prandial insulin response after mixed-meal test

Liraglutide → Post-prandial insulin response after mixed-meal test

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Postprandial blood glucose

Liraglutide → Postprandial blood glucose

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Liraglutide improved the disposition index by 40% (p<0.001).
Post-prandial glucose reduction was noted with liraglutide.
Glucagon levels remained unchanged during liraglutide therapy.

A quién se aplica

Adults with well-controlled type 2 diabetes.
Participants who are currently on metformin therapy.

Tener en Cuenta

Results may not be applicable to individuals with poorly controlled diabetes.
Further studies are needed to confirm long-term effects.
The study did not explore the effects of liraglutide in diverse populations.

Entre Líneas

Sample size for some outcomes was small, limiting generalizability.
Effectiveness of liraglutide compared to metformin and placebo remains unclear.
No long-term follow-up data were provided.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Disposition Index, GLP-1 Receptor Agonists and Glucagon.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → Disposition Index

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Glucagon

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

Disposition Index Evidence Hub

All studies measuring Disposition Index

1 studies

outcome_hub

Measures Disposition Index as a key outcome.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

1 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

Glucagon Evidence Hub

All studies measuring Glucagon

1 studies

outcome_hub

Measures Glucagon as a key outcome.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Liraglutide and Disposition Index

Intervention: LiraglutideOutcome: Disposition Index

1 results

All studies on Liraglutide and Glucagon

Intervention: LiraglutideOutcome: Glucagon

1 results

All studies on Liraglutide

Intervention: Liraglutide

1 results

All studies measuring Disposition Index

Outcome: Disposition Index

1 results

All studies measuring Glucagon

Outcome: Glucagon

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Does Liraglutide improve disposition index?

Emerging Evidence

Liraglutide appears to improve disposition index.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Disposition Index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Liraglutide improve glucagon?

Emerging Evidence

Current evidence does not show a clear benefit of Liraglutide for glucagon.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Glucagon
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Liraglutide improve insulin clearance?

Emerging Evidence

Current evidence does not show a clear benefit of Liraglutide for insulin clearance.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Insulin clearance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence Hub Post-Meal and OGTT Glucose Evidence Hub GLP-1 Receptor Agonists Evidence Hub Liraglutide Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Liraglutide and Disposition Index All studies on Liraglutide and Postprandial blood glucose All studies on Liraglutide and Glucagon All studies on Liraglutide and Insulin clearance

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patients GLP-1RA improves metabolic outcomes in MASLD Liraglutide 3 mg pathway improves weight loss.Liraglutide improves glycaemic control in adults with T2D

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.